LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]
LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham [Yahoo! Finance]
LB Pharmaceuticals (LBRX) is now covered by Craig Hallum. They set a "buy" rating and a $36.00 price target on the stock.
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]